Prostate Cancer Diagnostic Trial Reaches Enrollment Goal
The study evaluates a new imaging tool to help doctors identify high-risk prostate cancer before surgical procedures.
Updated on Oct. 27, 2026 in Cancer
Live Poll
Do you believe new diagnostic medical technologies typically offer enough benefit to justify their clinical adoption?
Clarity Pharmaceuticals has finished enrolling 383 participants in its Phase III CLARIFY clinical trial for high-risk prostate cancer. The study evaluates the diagnostic performance of a new imaging agent in patients scheduled for surgery.
Why it matters
Better imaging detection could eventually improve the accuracy of surgical planning for high-risk prostate cancer. The study is currently gathering data to support a potential New Drug Application with the FDA.
The Phase III CLARIFY trial has reached its target of 383 participants with high-risk prostate cancer undergoing surgery. Preliminary findings from the earlier Phase I PROPELLER study showed the imaging agent identified more lesions in 73% of cases compared to 27% using a standard alternative.
The players
Clarity Pharmaceuticals
A biotechnology firm developing radiopharmaceutical diagnostic and therapeutic products for oncology.
The details
The trial utilizes 64Cu-SAR-bisPSMA, a diagnostic imaging agent designed for positron emission tomography. Researchers are assessing its performance by comparing independent reviews of pelvic lymph nodes against post-surgical histopathology. This mechanism aims to provide high-resolution mapping of cancer spread in patients scheduled for a radical prostatectomy with pelvic lymph node dissection.
Timeline
October 27, 2026: Clarity Pharmaceuticals reached the enrollment goal.
First half of 2027: Topline study data is expected to be released.
Health Landscape
Advancements in prostate cancer diagnostics focus on improving imaging sensitivity to better guide surgical interventions. The CLARIFY trial sits within this broader effort to reduce uncertainty during pelvic lymph node dissection by utilizing more precise tracer technology.
This research is currently in the investigative stage and does not change your immediate care plan. If you have been diagnosed with high-risk prostate cancer, talk to your doctor about which imaging tools are currently part of the standard surgical planning process.
The takeaway
The CLARIFY trial represents an effort to improve the accuracy of imaging for high-risk prostate cancer. Patients currently navigating a diagnosis should consult their oncologist to understand how standard imaging protocols compare to new diagnostics in development.
Further reading
For more on evolving detection methods, see our coverage on Cancer.
More information
Review the full CLARIFY trial clinical study details on the official registry.
Source note: This article includes information reported by FNArena.
Live Poll
Do you believe new diagnostic medical technologies typically offer enough benefit to justify their clinical adoption?
